# Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)

> **NCT03732391** · PHASE2 · COMPLETED · sponsor: **CORTESI LAURA** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab 25 MG(milligram)/ML

## Key facts

- **NCT ID:** NCT03732391
- **Lead sponsor:** CORTESI LAURA
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-12
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-01-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03732391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03732391, "Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03732391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*